Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IP plus IV chemotherapy versus IV carboplatin plus paclitaxel in optimally debulked epithelial ovarian cancer
2009-012859-21Phase 2Terminated
- Sponsor
- Canadian Cancer Trials Group
- Start
- Jun 2010
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of paclitaxel, carboplatin and cisplatin in epithelial ovarian cancer (EOC) and ovarian cancer (2 arms), sponsored by Canadian Cancer Trials Group. Primary endpoints: Feasibility of intraperitoneal chemotherapy delivery and Selection of intraperitoneal arm after randomisation of 150 patients. Started Jun 2010; status: terminated.
02
Drugs
paclitaxelcarboplatincisplatin
03
Conditions
epithelial ovarian cancer (EOC)ovarian cancer
Beyond the preview
Go deeper on 2009-012859-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-012859-21.